首页> 外文OA文献 >FRI0523 Short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis: a network meta-analysis of randomised controlled trials

【2h】

FRI0523 Short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis: a network meta-analysis of randomised controlled trials

机译：Fri0523靶向IL-6，IL-12/23和IL-17用于活性银屑病关节炎的新生物剂的短期疗效和安全性：随机对照试验的网络META分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
W Dongze; Y Jiang; L-S Tam;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [J] . Fan Bai, Gang Gang Li, Qingmin Liu, Journal of immunology research. . 2019,第1期

机译：IL-17，IL-12/23和IL-23抑制剂Brodalumab，Secukinumab，Ixekizumab，Ustekizumab，Guselkumab，Tildrakizumab和Risankizumab的短期疗效和安全性用于治疗中度至重度斑块牛皮癣：系统审查和随机对照试验的网络荟萃分析
2. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial [J] . RitchlinC., RahmanP., KavanaughA., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第6期

机译：抗IL-12/23 p40单克隆抗体，Ustekinumab，在患有常规非生物和生物抗肿瘤坏死因子治疗的患者中，抗IL-12/23 p40单克隆抗体，Ustekinumab的功效和安全性：6个月和1年的第3阶段结果，多中心，双盲，安放的，随机的psummit 2试验
3. Comment on: Efficacy and safety of biologics targeting interleukin-6,-12/23 and-17 pathways for peripheral psoriatic arthritis: a network meta-analysis [J] . Lu Chenyang, Liu Yi Rheumatology . 2018,第11期

机译：评论：生物学靶向白细胞介素-6，-12 / 23和17途径的生物学和安全性，用于外周式银屑病关节炎：网络元分析
4. Short-Term Efficacy and Safety of IL-17 IL-12/23 and IL-23 Inhibitors Brodalumab Secukinumab Ixekizumab Ustekinumab Guselkumab Tildrakizumab and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [O] . Fan Bai, Gang Gang Li, Qingmin Liu, 2019

机译：IL-17IL-12 / 23和IL-23抑制剂BrodalumabSecukinumabIxekizumabUstekinumabGuselkumabTildrakizumab和Risankizumab治疗中度至重度斑块状牛皮癣的短期疗效和安全性：系统评价和随机对照试验的网络元分析
5. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [O] . Fan Bai, Gang Gang Li, Qingmin Liu, 2019

机译：IL-17，IL-12/23和IL-23抑制剂Brodalumab，Secukinumab，Ixekizumab，Ustekizumab，Guselkumab，Tildrakizumab和Risankizumab的短期疗效和安全性用于治疗中度至重度斑块牛皮癣：系统审查和随机对照试验的网络荟萃分析

FRI0523 Short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis: a network meta-analysis of randomised controlled trials

著录项

引文网络

相似文献

相关主题

期刊订阅